Full video transcriptClick to expand
Auto-generated transcript of @prettyauzhie's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Y'all this turns up and tag me so constipated y'all why I have to use a suppository
- 0:05Just the second day I didn't use one because I've been drinking mirror legs mirror legs mirror legs and
- 0:12Mirror like stop working. It was not working for me
- 0:15So I've been trying to have more
- 0:20Intake like liquids and stuff like to hydrate and get water in my system and stuff
- 0:26So the mirror less can do his job because y'all know mirror legs pools
- 0:30Water from your body to help get the stool moving and stuff or whatever
- 0:34So I can be I do a bad job at you know hydrating so I mean I'm trying to do better at that
- 0:41Because I know that can also
- 0:43Make you constipated
- 0:45Girl
- 0:47When I tell you this 15 milligrams. I'm never doing this again. I might do a little 12.5 and that's it because the 15
- 0:56She got me messed up
Tirzepatide on TikTok: separating real results from hype
Quick answer
The creator is on tirzepatide 15mg and experiencing constipation severe enough to require rectal suppository use, consistent with dose-dependent GI motility effects seen in SURMOUNT-1 trial data. She is self-managing with polyethylene glycol (MiraLAX) and attempting to improve hydration to support laxative efficacy. Her reported plan to step back to 12.5mg reflects a common clinical response to tolerability issues at the highest approved tirzepatide dose.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Tirzepatide on TikTok: separating real results from hype, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Tirzepatide on TikTok: separating real results from hype" from 💖Auzhie | R N Y💖. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is on tirzepatide 15mg and experiencing constipation severe enough to require rectal suppository use, consistent with dose-dependent GI motility effects seen in SURMOUNT-1 trial data.
The reason this review is not generic is the source wording and the canonical claim label "glp1 fyp fyp foryou glp1 glp1community tirzepatide." In this clip, the useful excerpt is: "Y'all this turns up and tag me so constipated y'all why I have to use a suppository Just the second day I didn't use one because I've been drinking mirror legs mirror legs mirror legs and Mirror like stop working." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator is on tirzepatide 15mg and experiencing constipation severe enough to require rectal suppository use, consistent with dose-dependent GI motility effects seen in SURMOUNT-1 trial data.
FormBlends verdict
Compounded Tirzepatide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is on tirzepatide 15mg and experiencing constipation severe enough to require rectal suppository use, consistent with dose-dependent GI motility effects seen in SURMOUNT-1 trial data. She is self-managing with polyethylene glycol (MiraLAX) and attempting to improve hydration to support laxative efficacy. Her reported plan to step back to 12.5mg reflects a common clinical response to tolerability issues at the highest approved tirzepatide dose.
- In SURMOUNT-1 (Jastreboff et al., 2022, NEJM), 17% of participants on tirzepatide 15mg reported constipation, nearly three times the placebo rate.
- MiraLAX works via osmotic pressure in the colon, not by pulling water from body tissues. Her mechanism description was close but not precise.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- In SURMOUNT-1 (Jastreboff et al., 2022, NEJM), 17% of participants on tirzepatide 15mg reported constipation, nearly three times the placebo rate.
- MiraLAX works via osmotic pressure in the colon, not by pulling water from body tissues. Her mechanism description was close but not precise.
- Murakami et al. (2007, European Journal of Nutrition) found low fluid intake is an independent risk factor for constipation, supporting her hydration logic.
- GLP-1 and GIP receptor agonism slows gastric emptying and reduces intestinal transit speed. This effect increases at higher doses.
- Needing a suppository for constipation while on tirzepatide warrants a conversation with your prescriber, not just symptom management at home.
- Dose-related GI side effects on tirzepatide often improve after several weeks at a stable dose. Rapid escalation increases the likelihood of severe symptoms.
- Any dose adjustments to tirzepatide, including stepping back from 15mg to 12.5mg, should involve your prescribing provider, not be self-directed based on side effect tolerance alone.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @prettyauzhie actually say?
She's on tirzepatide 15mg and got hit with bad constipation, bad enough to need a suppository. She says MiraLAX stopped working for her, and she thinks the reason is that she wasn't drinking enough water. Her logic: MiraLAX "pulls water from your body" to move stool, so if you're dehydrated, it can't do its job. She also says she's done with 15mg and may drop back to 12.5mg.
That's the full picture. No dramatic medical claims, just someone describing a rough GI experience and trying to troubleshoot it in real time. Some of what she said is directionally right. Some of it is a bit off on the mechanism. Let's get into it.
Does the science back this up?
Yes, constipation is one of the most documented side effects of tirzepatide, and it gets worse as doses increase. Her experience at 15mg tracks with the clinical data.
In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), constipation was reported in roughly 17% of participants on tirzepatide 15mg, compared to about 6% on placebo. That's not a small signal. The mechanism involves GLP-1 and GIP receptor activation slowing gastric motility and reducing intestinal transit speed. Your gut literally moves more slowly on higher doses.
Her MiraLAX observation also has a biological basis. Polyethylene glycol (PEG), the active ingredient in MiraLAX, is an osmotic laxative. It works by drawing water into the colon. If you're chronically under-hydrated, there's less free water available systemically, which can blunt that osmotic effect. Hydration doesn't make MiraLAX magic, but it does support the conditions under which it works best.
What did they get wrong (or right)?
She got the core pharmacology of MiraLAX mostly right, but slightly oversimplified. The mechanism is worth clarifying.
She says MiraLAX "pulls water from your body" to move stool. Technically, polyethylene glycol is not absorbed and works by retaining water already present in the gut lumen through osmotic pressure. It doesn't pull water out of your tissues the way a stimulant laxative might behave. But her practical point, that drinking more water helps MiraLAX work, is not wrong. Adequate hydration supports stool softness and colonic transit independent of any laxative.
What she got right: dose-dependent constipation is real. Her instinct to consider dropping back from 15mg to 12.5mg is consistent with standard titration thinking, where side effect burden sometimes warrants holding or stepping back a dose. She also correctly identifies herself as someone with poor baseline hydration habits as a contributing factor, which is clinically relevant. Poor fluid intake is an independent risk factor for constipation regardless of GLP-1 use (Murakami et al., 2007, European Journal of Nutrition).
What should you actually know?
If you're on tirzepatide and dealing with constipation, this is a known, manageable side effect, not a reason to panic or quit. But it does require actual intervention, not just hoping it resolves.
A few things worth knowing. First, constipation risk increases with dose escalation on tirzepatide. If you jump to a higher dose and your gut shuts down, that is an expected pharmacological response, not a fluke. Second, osmotic laxatives like MiraLAX are generally considered first-line for GLP-1-related constipation, and yes, hydration matters. Third, if you need a suppository two days in, that's a signal worth bringing to your prescriber, not just a TikTok. Severe constipation, straining, or any rectal bleeding should prompt a clinical conversation, not more MiraLAX.
Finally, dose decisions like moving from 15mg to 12.5mg are between you and your provider. Self-adjusting tirzepatide doses based on side effect tolerance is something your clinical team should be looped into. The right dose is the one that balances efficacy with tolerability, and that calculation is individual.
- Constipation affects roughly 1 in 6 people on tirzepatide 15mg based on trial data
- Hydration supports but does not replace osmotic laxative function
- GI side effects often improve after the first few weeks at a new dose
- Needing a suppository is a sign to contact your prescriber, not just push through
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
💖Auzhie | R N Y💖 · TikTok creator
3.0K views on this video
#fyp #fypシ #foryou #glp1 #glp1community #tirzepatide
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about in surmount-1 (jastreboff et al., 2022, nejm), 17% of participants?
In SURMOUNT-1 (Jastreboff et al., 2022, NEJM), 17% of participants on tirzepatide 15mg reported constipation, nearly three times the placebo rate.
What does the video say about miralax works via osmotic pressure in the colon, not by?
MiraLAX works via osmotic pressure in the colon, not by pulling water from body tissues. Her mechanism description was close but not precise.
What does the video say about murakami et al. (2007, european journal of nutrition) found low?
Murakami et al. (2007, European Journal of Nutrition) found low fluid intake is an independent risk factor for constipation, supporting her hydration logic.
What does the video say about glp-1?
GLP-1 and GIP receptor agonism slows gastric emptying and reduces intestinal transit speed. This effect increases at higher doses.
What does the video say about needing a suppository for constipation while on tirzepatide warrants a?
Needing a suppository for constipation while on tirzepatide warrants a conversation with your prescriber, not just symptom management at home.
Dose-related GI side effects on tirzepatide often improve after several weeks at a stable dose. Rapid escalation increases the likelihood of severe symptoms?
Dose-related GI side effects on tirzepatide often improve after several weeks at a stable dose. Rapid escalation increases the likelihood of severe symptoms.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by 💖Auzhie | R N Y💖, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.